Skip to main content
. Author manuscript; available in PMC: 2021 Nov 26.
Published in final edited form as: Neurosci Biobehav Rev. 2019 May 14;110:150–173. doi: 10.1016/j.neubiorev.2018.07.015

Fig. 4.

Fig. 4.

Effects of mephedrone on methamphetamine-induced reductions in striatal DA, DAT and TH (upper panels). Mice were treated with the indicated doses of mephedrone (MEPH) 30 min prior to each injection of 2.5 (●) or 5.0 mg/kg (■) methamphetamine (METH) and killed 2d later for determination of striatal levels of DA by HPLC or DAT and TH by immunoblotting. Effects of mephedrone (4 × 20 mg/kg) in combination with other amphetamines on DA, DAT and TH levels (bottom panels). Immunoblots for DAT and TH (lower panels) are numbered 1–8 to represent the following treatments: 1,5: control; 2,6: MEPH; 3: amphetamine (AMPH); 4: AMPH + MEPH; 7: MDMA; and 8: MDMA + MEPH. Data are mean ± SEM for 5–7 mice per group. Some error bars were too small to exceed the size of the symbols and are not visible. ***p < 0.001 versus controls and #p < 0.01, ##p < 0.001 or ###p < 0.0001 versus the respective dose of methamphetamine (Tukey’s multiple comparison test). Reprinted from Angoa-Perez et al. (2013) with permission from Wiley.